ClinicalTrials.gg

Program

zaltenibart

Also written as “OMS906 study drug” and “OMS906”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, led by Omeros.

Furthest: phase 2, since Jul 11, 20234 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Omeros41 open or runningphase 2since Jul 11, 2023May 4, 2023Dec 2026phase 2 · NCT06298955
  • Named in novo nordisk’s own pipeline as Zaltenibart in PNH, phase 2, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2023First study: phase 1 study in Hemoglobinuria, ParoxysmalFirst studyNCT05889299 · 15 enrolled · Ukraine
  2. Jul 11, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT05972967 · 12 enrolled · Germany, Greece, Switzerland and more
  3. Jan 4, 2024Phase 2 study in C3 GlomerulopathyNCT06209736 · 3 enrolled · Lithuania, New Zealand, Poland and more
  4. Feb 17, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06298955 · 25 enrolled · Germany, Switzerland, Ukraine and more
  5. Nov 2, 2026Phase 2 study terminatedStudy stoppedNCT06209736 · “The study was terminated for strategic reasons related to the molecule's recent acquisition”

Ahead

  1. Dec 2026Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06298955

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06298955Hemoglobinuria, Paroxysmal · Germany, Switzerland, Ukraine and more2Active, not recruitingDec 202625
NCT06209736C3 Glomerulopathy · Lithuania, New Zealand, Poland and more2TerminatedApr 14, 20263
NCT05972967Hemoglobinuria, Paroxysmal · Germany, Greece, Switzerland and more2CompletedOct 10, 202412
NCT05889299Hemoglobinuria, Paroxysmal · Ukraine1CompletedNov 3, 202515

How it is read

Names in the registry

  • “OMS906 study drug”, 2 entries
  • “OMS906”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.